· Event impact

Esperion Therapeutics to be Acquired by Archimed for $1.1 Billion

Type: Corporate ActionConfidence: 1Verified: unverified
Esperion Therapeutics announced a definitive agreement to be acquired by Archimed for approximately $1.1 billion. Shareholders will receive $3.16 per share in cash plus contingent value rights, representing a significant premium.

Transmission path

Company acquisition -> Share price appreciation for target company -> Sector consolidation

Extended read

Esperion Therapeutics (ESPR) shares surged following the announcement of a definitive acquisition agreement with Archimed. The deal values Esperion at approximately $1.1 billion, with shareholders set to receive $3.16 per share in cash, along with contingent value rights (CVRs). This offer represents a substantial 58% premium over Esperion's closing price on April 30. The acquisition highlights strategic consolidation within the biotechnology and pharmaceutical sectors, potentially driven by Archimed's interest in Esperion's drug pipeline or market position.

Exposed assets

ESPR

Continuous event tracking, options routing, and portfolio overlap for this event and the assumptions it moves live inside Market Ontology. Start a trial →